Nivolumab plus standard treatment for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or inoperable stomach or esophageal cancer that has spread or cannot be removed.
- Your tumor tested positive for PD-L1 (CPS of 1 or higher) and is microsatellite stable and HER2 negative.
- Your cancer got worse or you had side effects from a first line of treatment that included chemotherapy plus an immunotherapy like nivolumab or pembrolizumab.
- You are at least 18 years old and in fairly good health (able to care for yourself, up and about more than half the day).
- You do not have a serious autoimmune disease, active bleeding, or a history of severe side effects from immunotherapy that caused you to stop treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
This trial tests three drugs together (futibatinib, paclitaxel, and ramucirumab) to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Hear when a new Advanced Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.